儿童严重脓毒症的连续性肾脏替代治疗:一项倾向评分匹配的前瞻性多中心PICU队列研究
该研究为倾向评分匹配的前瞻性多中心队列研究,纳入中国4家三级大学儿童医院PICU在2016年7月至2018年6月连续收治的324例严重脓毒症患儿,分为连续性肾脏替代治疗组和常规(非连续性肾脏替代治疗)组。连续性肾脏替代治疗组住院病死率为35.6%(64/180),非连续性肾脏替代治疗组为47.9%(69/144);倾向评分调整后分别为21.3%(29/136)和32.4%(44/136)。亚组分析中,仅合并急性呼吸窘迫综合征的患儿死亡相对风险为0.447(95%CI 0.208-0.961,p=0.037)。连续性肾脏替代治疗平均时长45小时(26-83小时),超滤率50 mL/kg/hr。
要点
- 倾向评分调整后,连续性肾脏替代治疗组住院病死率21.3%(29/136)低于非连续性肾脏替代治疗组32.4%(44/136)。
- 仅合并急性呼吸窘迫综合征的患儿中,连续性肾脏替代治疗与死亡相对风险0.447(95%CI 0.208-0.961,p=0.037)相关。
- 在合并休克、急性肾损伤、急性肝功能障碍、脑病及液体过负荷大于10%的患儿中,未见相应关联。
- 连续性肾脏替代治疗平均时长45小时(26-83小时),超滤率50 mL/kg/hr。
- 连续性肾脏替代治疗组白细胞介素-6水平下降,自然杀伤细胞百分比改善。
适用人群与场景
- 中国4家三级大学儿童医院PICU在2016年7月至2018年6月连续收治的严重脓毒症患儿,共324例。
- 分为连续性肾脏替代治疗组(180例)和常规非连续性肾脏替代治疗组(144例)。
处置流程与药物剂量
- 连续性肾脏替代治疗平均时长45小时(26-83小时),超滤率50 mL/kg/hr。
研究设计与关键结果
- 研究类型为倾向评分匹配的前瞻性多中心队列研究,纳入324例严重脓毒症患儿,来自中国4家三级大学儿童医院PICU。
- 住院病死率:连续性肾脏替代治疗组35.6%(64/180) vs 非连续性肾脏替代治疗组47.9%(69/144)。
- 倾向评分调整后住院病死率:连续性肾脏替代治疗组21.3%(29/136) vs 非连续性肾脏替代治疗组32.4%(44/136)。
- 亚组分析:仅合并急性呼吸窘迫综合征的患儿中,死亡相对风险0.447(95%CI 0.208-0.961,p=0.037);合并休克、急性肾损伤、急性肝功能障碍、脑病及液体过负荷大于10%的患儿中未见相应关联。
- 连续性肾脏替代治疗平均时长45小时(26-83小时),超滤率50 mL/kg/hr。
- 连续性肾脏替代治疗组较非连续性肾脏替代治疗组白细胞介素-6水平下降,自然杀伤细胞百分比改善。
- 连续性肾脏替代治疗是儿童严重脓毒症住院死亡的独立显著风险因素;在接受连续性肾脏替代治疗的患者中,连续性肾脏替代治疗启动与PICU入住之间的间隔是住院死亡的独立风险因素。
证据类型、等级与局限
- 证据类型:倾向评分匹配的前瞻性多中心队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,以50 mL/kg/hr超滤率行连续性肾脏替代治疗可降低儿童严重脓毒症住院病死率,尤其对合并急性呼吸窘迫综合征的患儿。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Continuous renal replacement therapy becomes available utilization for pediatric critically ill, but the impact of mortality rate in severe sepsis remains no consistent conclusion. The aim of the study is to assess the effect of continuous renal replacement therapy in pediatric patients with severe sepsis and the impact this therapy may have on their mortality.
DESIGN: Propensity score-matched cohort study analyzing data prospectively collected by the PICUs over 2 years (2016-2018).
SETTING: Four PICUs of tertiary university children's hospital in China.
PATIENTS: The consecutive patients with severe sepsis admitted to study PICUs were enrolled from July 2016 to June 2018.
INTERVENTIONS: The patients were divided into the continuous renal replacement therapy group and the conventional (noncontinuous renal replacement therapy) group.
MEASUREMENTS AND MAIN RESULTS: A total of 324 patients with severe sepsis were enrolled. The hospital mortality rate was 35.6% (64/180) in the continuous renal replacement therapy group and 47.9% (69/144) in the noncontinuous renal replacement therapy group. After propensity score adjustment, the hospital mortality rate was 21.3% (29/136) in the continuous renal replacement therapy group and 32.4% (44/136) in the noncontinuous renal replacement therapy group. In subgroup analysis, the relative risk of dying was 0.447 (95% CI, 0.208-0.961) only in patients complicated by acute respiratory distress syndrome (p = 0.037), but not in patients with shock, acute kidney injury, acute liver dysfunction, encephalopathy, and fluid overload greater than 10%. The mean duration of continuous renal replacement therapy was 45 hours (26-83 hr) with an ultrafiltration rate of 50 mL/kg/hr. The level of interleukin-6 was decreased, and the percent of natural killer cells (%) was improved in the continuous renal replacement therapy group compared with the noncontinuous renal replacement therapy group. Furthermore, continuous renal replacement therapy was an independently significant risk factor for hospital mortality in pediatric patients with severe sepsis, and the interval between continuous renal replacement therapy initiation and PICU admission was an independent risk factor for hospital mortality in patients receiving continuous renal replacement therapy.
CONCLUSIONS: Continuous renal replacement therapy with an ultrafiltration rate of 50 mL/kg/hr decreases hospital mortality rate in pediatric severe sepsis, especially in patients with acute respiratory distress syndrome.
参考来源
- Miao H, Shi J, Wang C, et al. Continuous Renal Replacement Therapy in Pediatric Severe Sepsis: A Propensity Score-Matched Prospective Multicenter Cohort Study in the PICU. Crit Care Med. 2019. PMID: 31369427. doi:10.1097/CCM.0000000000003901
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。